In the past week, OGN stock has gone down by -2.39%, with a monthly gain of 16.25% and a quarterly plunge of -36.32%. The volatility ratio for the week is 1.81%, and the volatility levels for the last 30 days are 2.40% for Organon & Co The simple moving average for the past 20 days is 1.99% for OGN’s stock, with a -33.29% simple moving average for the past 200 days.
Is It Worth Investing in Organon & Co (NYSE: OGN) Right Now?
The price-to-earnings ratio for Organon & Co (NYSE: OGN) is above average at 3.39x, Company’s 36-month beta value is 0.55.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for OGN is 258.99M, and currently, short sellers hold a 6.75% ratio of that floaft. The average trading volume of OGN on June 24, 2025 was 5.97M shares.
OGN) stock’s latest price update
Organon & Co (NYSE: OGN)’s stock price has increased by 3278546 compared to its previous closing price of 9.75. However, the company has seen a -2.39% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Analysts’ Opinion of OGN
JP Morgan, on the other hand, stated in their research note that they expect to see OGN reach a price target of $20, previously predicting the price at $18. The rating they have provided for OGN stocks is “Underweight” according to the report published on September 06th, 2024.
Goldman gave a rating of “Neutral” to OGN, setting the target price at $16 in the report published on November 03rd of the previous year.
OGN Trading at -1.37% from the 50-Day Moving Average
After a stumble in the market that brought OGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.58% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OGN starting from COX CARRIE SMITH, who purchase 12,469 shares at the price of $8.07 back on May 14 ’25. After this action, COX CARRIE SMITH now owns 12,469 shares of Organon & Co, valued at $100,591 using the latest closing price.
Falcione Aaron, the Chief Human Resources Officer of Organon & Co, purchase 5,500 shares at $8.77 during a trade that took place back on May 07 ’25, which means that Falcione Aaron is holding 62,974 shares at $48,235 based on the most recent closing price.
Stock Fundamentals for OGN
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.57 for the gross margin
The net margin for Organon & Co stands at 0.12. The total capital return value is set at 0.13. Equity return is now at value 254.24, with 5.99 for asset returns.
Based on Organon & Co (OGN), the company’s capital structure generated 0.94 points at debt to capital in total, while cash flow to debt ratio is standing at 0.1. The debt to equity ratio resting at 16.52. The interest coverage ratio of the stock is 2.72.
Currently, EBITDA for the company is 1.61 billion with net debt to EBITDA at 5.61. When we switch over and look at the enterprise to sales, we see a ratio of 1.74. The receivables turnover for the company is 4.32for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
In a nutshell, Organon & Co (OGN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
